Cyveen Weerarantha | Digital Health and Computational Biology | Research Excellence Award

Published on by Computational Biologists

Research Excellence Award

Cyveen Weeraratna
Affiliation Royal Melbourne Hospital
Country Australia
Scopus ID 56151709400
Documents 4
Citations 70
h-index 3
Subject Area Digital Health and Computational Biology
Event Computational Biologists Awards
ORCID 0009-0000-6689-4623

Cyveen Weeraratna
Royal Melbourne Hospital

Cyveen Weerarantha is affiliated with the Royal Melbourne Hospital, Australia, and has contributed to research spanning digital health and computational biology. The Research Excellence Award recognizes scholarly achievements that demonstrate scientific quality, interdisciplinary collaboration, and measurable research influence. Within this context, the researcher represents an emerging contributor whose published work, citation record, and involvement in computational health research align with the objectives of academic recognition and professional excellence.[1]

Abstract

The Research Excellence Award recognizes investigators whose scholarly activities demonstrate sustained scientific quality, meaningful research impact, and contributions to advancing knowledge within their discipline. Cyveen Weerarantha’s academic profile reflects involvement in digital health and computational biology through publications that support data-driven healthcare research and interdisciplinary collaboration. Bibliometric indicators, including publications, citations, and an established h-index, provide measurable evidence of scholarly engagement. These achievements, combined with institutional affiliation and participation in computational health research, illustrate an emerging academic profile consistent with the principles of excellence, innovation, research integrity, and professional contribution.[1][2]

Keywords

Digital Health, Computational Biology, Biomedical Informatics, Clinical Research, Health Data Analytics, Research Excellence, Scientific Impact, Translational Medicine.

Introduction

Digital health and computational biology continue to reshape biomedical research by integrating advanced computational techniques with clinical practice and biological sciences. Researchers working within these domains contribute to improved diagnostic methodologies, health data interpretation, and evidence-based decision making. Recognition through research awards reflects scientific productivity together with ethical scholarship, interdisciplinary collaboration, and measurable academic influence within evolving healthcare environments.[2]

Research Profile

Cyveen Weerarantha is associated with the Royal Melbourne Hospital in Australia and maintains an indexed publication record within Scopus. Research activities emphasize computational approaches supporting healthcare research, reflecting collaboration across clinical and data science disciplines. Bibliometric indicators demonstrate developing academic influence supported by published literature and citation performance that contributes to ongoing scientific communication and knowledge dissemination.[1]

Research Contributions

The research contributions associated with this profile emphasize computational analysis applied to healthcare challenges, integrating biological information with digital technologies to improve research methodologies. Such work supports evidence generation, promotes interdisciplinary collaboration, and contributes to broader understanding of data-driven healthcare solutions. These efforts reflect the growing importance of computational biology in modern clinical research and biomedical innovation.[3]

Publications

The researcher has four indexed publications that collectively contribute to the scientific literature within digital health and computational biology. Citation activity demonstrates continuing academic visibility, while publication in peer-reviewed venues supports knowledge exchange and encourages future collaborative investigations. Published studies provide a measurable foundation for evaluating research productivity and scholarly engagement within the discipline.[1]

Research Impact

Research impact is commonly evaluated through publication quality, citation performance, scholarly visibility, and contribution to advancing scientific understanding. The available bibliometric indicators demonstrate meaningful engagement with the academic community, while interdisciplinary research strengthens the relevance of computational approaches within healthcare. Such measurable outcomes support recognition through professional and institutional award programs.[4]

Award Suitability

The Research Excellence Award acknowledges researchers demonstrating scientific rigor, measurable scholarly achievement, and continuing contributions to their academic field. Cyveen Weerarantha’s publication record, citation metrics, institutional affiliation, and research focus within computational biology and digital health collectively align with the evaluation principles commonly applied to emerging research excellence awards, emphasizing quality, collaboration, and sustained scholarly development.[1][4]

Conclusion

Cyveen Weerarantha’s scholarly profile illustrates an emerging contribution to computational biology and digital health supported by indexed publications, citations, and interdisciplinary collaboration. These characteristics reflect academic engagement that is consistent with the objectives of the Research Excellence Award, recognizing research quality, scientific integrity, and the advancement of evidence-based healthcare through computational innovation.[1]

References

  1. Elsevier. (n.d.). Scopus Author Details: Cyveen Weerarantha, Author ID 56151709400. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=56151709400
  2. American Journal of Kidney Diseases. (2018). Attempts to Change the Globally Accepted Term, CKDu, to KDUCAL, NUCAL, or CINAC Are Inappropriate..
    https://doi.org/10.1053/j.ajkd.2018.01.033
  3. Critical Care and Resuscitation. (2026). Sustainable continuous renal replacement therapy: The influence of blood flow rates, effluent dose, autoeffluent, and citrate anticoagulation on carbon dioxide emissions.
    https://doi.org/10.1016/j.ccrj.2026.100176
  4. Computational Biologists Awards. Research Excellence Award.
    https://computationalbiologists.com/

Weiling He | Cancer Genomics Computational Studies | Best Researcher Award

Published on by Computational Biologists

Prof. Weiling He | Cancer Genomics Computational Studies | Best Researcher Award

Professor at Xiamen University, China

Dr. Weiling He is a leading figure in precision oncology, serving as Chief Physician, Professor, Doctoral and Postdoctoral Supervisor, and President of Xiang’an Hospital at Xiamen University. He is widely recognized for his contributions to cancer treatment, particularly in the domains of tumor microenvironments and drug resistance. Honored with the National Natural Science Foundation of China’s Excellent Young Scientist Fund and recognized as a Distinguished Young Medical Talent of Guangdong Province, Dr. He has established himself as a trailblazer in translational medical research. His prolific output includes over 50 SCI-indexed publications and six granted patents, underscoring his influence in both academia and clinical application.

Profile

Scopus

Education

Dr. He holds both an MD and a PhD, equipping him with a robust foundation for navigating the complex landscape of cancer research and treatment. His academic journey reflects a commitment to scientific excellence and multidisciplinary learning, enabling him to bridge the gap between theoretical research and clinical practice. The integration of medicine and scientific inquiry during his training shaped his ongoing work in precision medicine, translational oncology, and systems biology.

Experience

With a career marked by leadership and innovation, Dr. He currently serves as the President of Xiang’an Hospital at Xiamen University. He has led more than 20 research projects at the national and provincial levels, including prestigious programs under the National Key R&D Initiative and the National Natural Science Foundation of China. Dr. He has also contributed extensively to industry-academia collaboration, participating in strategic projects like the Guangdong Soft Science Program and the Guangzhou Future Industry Initiative. His academic affiliations include leadership roles in over ten national medical associations, reflecting a deep engagement with both clinical and academic ecosystems.

Research Interest

Dr. He’s research focuses on unraveling the mechanisms of tumor drug resistance, exploring metastasis pathways, and analyzing the tumor microenvironment. He is particularly interested in precision interventional therapy and the development of biomaterials and microfluidic technologies for real-time monitoring and treatment. His interdisciplinary approach combines oncology, engineering, and systems biology to improve the outcomes of metastatic cancer therapies. Through collaborative research with institutions such as Sun Yat-sen University and Emory University, he advances new methodologies in clinical translation and integrative cancer treatment.

Award

Dr. Weiling He has received several distinguished honors throughout his career. Among them, the National Natural Science Foundation of China awarded him the Excellent Young Scientist Fund, recognizing his outstanding potential and research impact in oncology. In addition, he was named a Distinguished Young Medical Talent of Guangdong Province, affirming his influence on medical innovation and leadership. His work is frequently acknowledged in national and international forums, and he has played a pivotal role in advancing precision medicine initiatives across China.

Publication

Dr. He has authored more than 50 papers indexed in SCI journals, with several appearing in top-tier publications. Notable recent works include:

“Immune Microenvironment Remodeling in Colorectal Cancer,” Cancer Immunology Research, 2020 – cited 326 times.

“Dual Nanoparticle Delivery in Precision Oncology,” Advanced Science, 2021.

“Microfluidic Chips for Real-time Tumor Monitoring,” Nature Communications, 2022.

“Translational Biomaterials in Interventional Therapy,” Science Translational Medicine, 2023 (cover article).

“Integrated Oncology Systems for Drug Resistance,” Nature Cancer, 2023.

“Microsphere Technology for Metastatic Cancer,” Advanced Science, 2024.

“Tumor Sensitization Targets for Interventional Therapy,” Nature Communications, 2024.

These publications have garnered over 1000 citations in total, with multiple works recognized as “Highly Cited Papers” in their respective fields.

Conclusion

Dr. Weiling He’s exceptional academic record, impactful research, numerous high-impact publications, robust patent portfolio, and her pivotal role in the advancement of precision oncology mark her as a standout candidate for the Best Researcher Award. Her commitment to interdisciplinary innovation and translational impact makes her not only deserving of this honor but a role model for future generations in computational and medical biology.

Nazanin Zounemat-Kermani | Computational Systems Medicine | Best Researcher Award

Published on by Computational Biologists

Dr Nazanin Zounemat-Kermani | Computational Systems Medicine | Best Researcher Award

Dr. Nazanin Zounemat-Kermani is an accomplished biomedical data scientist whose research stands at the forefront of precision medicine, respiratory disease, and artificial intelligence. Currently serving as a Postdoctoral Research Associate at both the National Heart and Lung Institute (NHLI) and the Data Science Institute (DSI) at Imperial College London, she has earned international recognition for her leadership in multi-omics data integration and machine learning applications in health sciences.

Profile:

🎓 Educational Background:

Dr. Kermani’s academic journey reflects a rare interdisciplinary blend of computer science and biomedical research. She holds a PhD in Biomedicine from Imperial College London (2020), following dual master’s degrees in Artificial Intelligence from the University of Amsterdam (2011) and Machine Learning and Robotics from the University of Tehran (2004). Her academic roots trace back to a Bachelor of Engineering in Software Engineering from Ferdowsi University of Mashhad (2002).

💼 Professional Experience:

Since 2020, Dr. Kermani has worked as a Postdoctoral Research Associate at Imperial College London, after several years as a Research Assistant and PhD candidate in Zoltan Takats’ Lab. Her academic trajectory within one of the world’s top institutions reflects both her scientific rigor and leadership capabilities.

🎓🤝 Academic Mentorship:

Dr. Nazanin Zounemat-Kermani is widely respected not only for her scientific contributions but also for her unwavering commitment to mentorship and academic leadership. Throughout her career, she has actively nurtured the growth of early-career scientists, postdoctoral researchers, and graduate students. As a senior member of interdisciplinary consortia such as AI-RESPIRE, PRISM, and U-BIOPRED, she has led cross-functional teams spanning clinical science, data engineering, and machine learning—mentoring junior colleagues in both technical development and scientific publishing. Her leadership style is inclusive and empowering, emphasizing hands-on guidance in areas such as statistical modeling, research communication, and responsible data science.

🏆 Awards and Honors:

Dr. Kermani has received numerous accolades, including the MSACL Young Investigator Award (2016), Scholar Awards from the American Thoracic Society (2022, 2023), and multiple research grants from prestigious bodies such as the UKRI, MRC, and EPSRC. She has also been invited to present her research by eminent scholars at institutions like Oxford University and Amsterdam UMC.

🌍 Global Projects and Leadership

Dr. Kermani has led and contributed to numerous high-impact international projects, including:

  • RASP-UK: She developed a robust data management platform supporting clinical and omics data integration for asthma research.

  • PIONEER: Co-led machine learning initiatives in prostate cancer, resulting in a key senior-author publication.

  • U-BIOPRED: Coordinated Europe’s largest severe asthma cohort study, publishing over 20 peer-reviewed articles and acting as corresponding author on influential multi-omics studies.

  • UK-Korea PRISM: Leads cross-national efforts in asthma pathophysiology using advanced analytics and single-cell data.

  • AI-RESPIRE: Heads AI model development for environmental and physiological time-series data, mentoring early-career researchers.

  • DeVENT and PROmics: Oversees analysis in critical care and deep learning integration in patient-reported outcomes.

📚 Publications:

  1. CC16 Confers Protection Against Influenza A Virus Infection in Human Airway Epithelium
    H. Kimura, N.Z. Kermani, N. Kimura, M.M. Siddiq, D. Francisco, I.M. Adcock, et al.
    American Journal of Respiratory and Critical Care Medicine, Vol. 211 (Abstracts), 2025.

  2. Distinct Single-Cell Transcriptional Profile in CD4⁺ T-Lymphocytes Among Obese Children With Asthma
    V. Tejwani, R. Wang, A. Villabona-Rueda, K. Suresh, T.D. Wu, I.M. Adcock, et al.
    American Journal of Physiology – Lung Cellular and Molecular Physiology, Vol. 328(3), 2025.

  3. Female Sex Hormones and the Oral Contraceptive Pill Modulate Asthma Severity Through GLUT-1
    A.C. Brown, O.R. Carroll, J.R. Mayall, N. Zounemat-Kermani, S.L.E. Vinzenz, et al.
    Mucosal Immunology, 2025.

  4. Neutrophilic Inflammation in Sputum or Blood Does Not Define a Clinically Distinct Asthma Phenotype in ATLANTIS
    P.J.M. Kuks, T.M. Kole, M. Kraft, S. Siddiqui, L.M. Fabbri, K.F. Rabe, A. Papi, et al.
    ERJ Open Research, Vol. 11(1), 2025.

  5. The Role of WNT5a and TGF‐β1 in Airway Remodelling and Severe Asthma
    T. Daud, S. Roberts, N. Zounemat-Kermani, M. Richardson, L.G. Heaney, et al.
    Allergy, 2025.

  6. Clinical Importance of Patient-Reported Outcome Measures in Severe Asthma: Results from U-BIOPRED
    R. Meys, F.M.E. Franssen, A.J. Van ‘t Hul, P.S. Bakke, M. Caruso, B. Dahlén, et al.
    Health and Quality of Life Outcomes, Vol. 22(1), Article 109, 2024.

  7. Radiomultiomics: Quantitative CT Clusters of Severe Asthma Associated With Multiomics
    N.Z. Kermani, K.F. Chung, G. Macis, G. Santini, F.A.A. Clemeno, A. Versi, K. Sun, et al.
    European Respiratory Journal, Vol. 64(5), 2024.

  8. S12 Association Between Disease Duration and FEV1 in Severe Asthma Phenotypes and Endotypes
    F. Yang, N. Zounemat-Kermani, P. Dixey, I.M. Adcock, C.I. Bloom, K.F. Chung
    Thorax, Vol. 79(Suppl 2), A15–A16, 2024.

  9. S120 Post-Hoc Analysis of Transcriptomic and Clinical Predictors of Remission in the ATLANTIS Cohort
    A.A. Kumar, T.M. Kole, M.C. Nawijn, K.F. Rabe, A. Papi, C. Brightling, D. Singh, et al.
    Thorax, Vol. 79(Suppl 2), A83–A84, 2024.

  10. Discovery and Validation of a Volatile Signature of Eosinophilic Airway Inflammation in Asthma
    R. Peltrini, R.L. Cordell, M. Wilde, S. Abuhelal, E. Quek, N. Zounemat-Kermani, et al.
    American Journal of Respiratory and Critical Care Medicine, Vol. 210(9), pp. 1101–1112, 2024.

  11. Cardiovascular Events in CML Patients Treated With Nilotinib: Validation of the HFA-ICOS Baseline Risk Score
    M. Andres, F. Fernando, S. Claudiani, N. Kermani, G. Ceccarelli, J. Apperley, et al.
    European Heart Journal, Vol. 45(Suppl 1), ehae666.3169, 2024.

  12. Scientific Business Abstracts
    F. Cooles, G. Vidal-Pedrola, N. Naamane, A. Pratt, B. Barron-Millar, et al.
    QJM: An International Journal of Medicine, Article hcae157, 2024.

  13. A Severe Asthma Phenotype of Excessive Airway Haemophilus influenzae Relative Abundance Associated With Sputum Neutrophilia
    A. Versi, A. Azim, F.X. Ivan, M.I. Abdel-Aziz, S. Bates, J. Riley, M. Uddin, et al.
    Clinical and Translational Medicine, Vol. 14(9), e70007, 2024.

  14. Host-Microbial Interactions Differ With Age of Asthma Onset
    A. Versi, A. Azim, F.X. Ivan, M.I. Abdel-Aziz, S. Bates, J. Riley, et al.
    European Respiratory Journal, 2024.

  15. Cardiovascular Events in CML Patients Treated With Nilotinib: Validation of the HFA-ICOS Baseline Risk Score
    F. Fernando, M.S. Andres, S. Claudiani, N.Z. Kermani, G. Ceccarelli, A.J. Innes, et al.
    Cardio-Oncology, Vol. 10(1), Article 42, 2024.

  16. Endotypes of Severe Neutrophilic and Eosinophilic Asthma From Multi-Omics Integration of U-BIOPRED Sputum Samples
    N.Z. Kermani, C.X. Li, A. Versi, Y. Badi, K. Sun, M.I. Abdel-Aziz, M. Bonatti, et al.
    Clinical and Translational Medicine, Vol. 14(7), e1771, 2024.

  17. IL-33 Induced Gene Expression in Activated Th2 Effector Cells Is Dependent on IL-1RL1 Haplotype and Asthma Status
    A.K.S. Jayalatha, M.E. Ketelaar, L. Hesse, Y.E. Badi, N. Zounemat-Kermani, et al.
    European Respiratory Journal, Vol. 63(6), 2024.

  18. Comparison of Asthma Phenotypes in Severe Asthma Cohorts (SARP, U-BIOPRED, ProAR and COREA) From Four Continents
    S.Y. Park, S. Fowler, D.E. Shaw, I.M. Adcock, A.R. Sousa, R. Djukanovic, et al.
    Allergy, Asthma & Immunology Research, Vol. 16(4), p. 338, 2024.

  19. Enose-Derived Response Clusters in Severe Asthmatics Treated With Anti-IL5/5R Biologics
    P. Dixey, N. Zounemat-Kermani, K. Raby, P.K. Bhavsar, K.F. Chung
    B16. Novel Insights Into Asthma Pathogenesis, A3013, 2024.

  20. Association of CC16 Expression in the Airways With Signature Expression of Multi-Omics Data
    H. Kimura, N.Z. Kermani, I.M. Adcock, K.F. Chung, M. Kraft
    D91. Bridging the Gap: Translational Studies in ARDS, Pneumonia, and Sepsis, 2024.